Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis

Brain

Volumn 136, Issue 11, 2013, Pages 3305-3332

  Nardo, Giovanni ^a,c   Iennaco, Raffaele ^a   Fusi, Nicolò ^b   Heath, Paul R ^c   Marino, Marianna ^a   Trolese, Maria C ^a   Ferraiuolo, Laura ^c   Lawrence, Neil ^b   Shaw, Pamela J ^c   Bendotti, Caterina ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Genetic background; Immune system; Motor neurons; SOD1

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ANGIOGENIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; COMPLEMENT COMPONENT C3; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIN D1; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 9; JANUS KINASE 1; JANUS KINASE 2; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 5; ONCOSTATIN M; ONCOSTATIN M RECEPTOR; PROTEIN C FOS; PROTEIN KINASE TYK2; SNARE PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; SYNAPTOBREVIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR SOX6; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE E3; UNCOUPLING PROTEIN 2;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; COLORIMETRY; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; IMMUNE RESPONSE GENE; IMMUNITY; IMMUNOBLOTTING; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; LASER CAPTURE MICRODISSECTION; LIFESPAN; LUMBAR SPINAL CORD; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROARRAY ANALYSIS; MOTONEURON; MOUSE; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; NUCLEAR PORE COMPLEX; ONCOGENE C FOS; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; STABLE EXPRESSION; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; TRANSGENE; TRANSGENIC MOUSE; UPREGULATION; WESTERN BLOTTING;

EID: 84890469438     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt250     Document Type: Article

References (182)

1. Adalbert R, Coleman MP. Axon pathology in age-related neurodegenerativedis orders. Neuropathol Appl Neurobiol 2013; 39: 90-108.
2. Antel JP, Arnason BG, Fuller TC, Lehrich Jr. Histocompatibility typing in amyotrophic lateral sclerosis. Arch Neurol 1976; 33: 423-5.
3. Aparicio-Erriu IM, Prehn JH. Molecular mechanisms in amyotrophic lateral sclerosis: the role of angiogenin, a secreted RNase. Front Neurosci 2012; 6: 167.
4. Appel SH, Beers DR, Henkel JS. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listeninǧTrends Immunol 2010; 31: 7-17.
5. Ashley C, Pastushok L, McKenna S, Ellison MJ, Xiao W. Roles of mouse UBC13 in DNA postreplication repair and Lys63-linked ubiquitination. Gene 2002; 285: 183-91.
6. Baker BJ, Akhtar LN, Benveniste EN. SOCS1 and SOCS3 in the control of CNS immunity. Trends Immunol 2009; 30: 392-400.
7. Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 2010; 48: 629-41.
8. Baron P, Bussini S, Cardin V, Corbo M, Conti G, Galimberti D, et al. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve 2005; 32: 541-4.
9. Basso M, Samengo G, Nardo G, Massignan T, D'Alessandro G, Tartari S, et al. Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS One 2009; 4: e8130.
10. Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4 + T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci USA 2008; 105: 15558-63.
11. Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 2011; 134: 1293-314.
12. Beghi E, Mennini T, Bendotti C, Bigini P, Logroscino G, Chioa, et al. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem 2007; 14: 3185-200.
13. Bendotti C, Carrì MT. Lessons from models of SOD1-linked familial ALS. Trends Mol Med 2004; 10: 393-400.
14. Bendotti C, Marino M, Cheroni C, Fontana E, Crippa V, Poletti A, et al. Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response. Prog Neurobiol 2012; 97: 101-26.
15. Benoit ME, Tenner AJ. Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J Neurosci 2011; 31: 3459-69.
16. Bhosle RC, Michele DE, Campbell KP, Li Z, Robson RM. Interactions of intermediate filament protein synemin with dystrophin and utrophin. Biochem Biophys Res Commun 2006; 346: 768-77.
17. Bilsland LG, Sahai E, Kelly G, Golding M, Greensmith L, Schiavo G. Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci USA 2010; 107: 20523-8.
18. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006a; 312: 1389-92.
19. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006b; 52: 39-59.
20. Boulanger LM, Huh GS, Shatz CJ. Neuronal plasticity and cellular immunity: shared molecular mechanisms. Curr Opin Neurobiol 2001; 11: 568-78.
21. Boulanger LM, Shatz CJ. Immune signalling in neural development, synaptic plasticity and disease. Nat Rev Neurosci 2004; 5: 521-31.
22. Brown SL, Sekhar KR, Rachakonda G, Sasi S, Freeman ML. Activating transcription factor 3 is a novel repressor of the nuclear factor erythroid-derived 2-related factor 2 (Nrf2)-regulated stress pathway. Cancer Res 2008; 68: 364-8.
23. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al. The transcriptional landscape of the mammalian genome. Science 2005; 309: 1559-63.
24. Chaineau M, Danglot L, Galli T. Multiple roles of the vesicular-SNARE TIVAMP in post-Golgi and endosomal trafficking. FEBS Lett 2009; 583: 3817-26.
25. Chatterton JE, Hirsch D, Schwartz JJ, Bickel PE, Rosenberg RD, Lodish HF, et al. Expression cloning of LDLB, a gene essential for normal Golgi function and assembly of the ldlCp complex. Proc Natl Acad Sci USA 1999; 96: 915-20.
26. Chen HJ, Anagnostou G, Chai A, Withers J, Morris A, Adhikaree J, et al. Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. J Biol Chem 2010; 285: 40266-81.
27. Chen SH, Benveniste EN. Oncostatin M: a pleiotropic cytokine in the central nervous system. Cytokine Growth Factor Rev 2004; 15: 379-91.
28. Chen SH, Gillespie GY, Benveniste EN. Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases. Glia 2006; 53: 191-200.
29. Cheroni C, Marino M, Tortarolo M, Veglianese P, De Biasi S, Fontana E, et al. Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum Mol Genet 2009; 18: 82-96.
30. Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci USA 2008; 105: 17913-8.
31. Chiu IM, Phatnani H, Kuligowski M, Tapia JC, Carrasco MA, Zhang M, et al. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc Natl Acad Sci USA 2009; 106: 20960-5.
32. Cho KI, Cai Y, Yi H, Yeh A, Aslanukov A, Ferreira PA. Association of the kinesin-binding domain of RanBP2 to KIF5B and KIF5C determines mitochondria localization and function. Traffic 2007; 8: 1722-35.
33. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2: 806-19.
34. Cooper-Knock J, Kirby J, Ferraiuolo L, Heath PR, Rattray M, Shaw PJ. Gene expression profiling in human neurodegenerative disease. Nat Rev Neurol 2012; 8: 518-30.
35. Corriveau RA, Huh GS, Shatz CJ. Regulation of class I MHC gene expression in the developing and mature CNS by neural activity. Neuron 1998; 21: 505-20.
36. Cox LE, Ferraiuolo L, Goodall EF, Heath PR, Higginbottom A, Mortiboys H, et al. Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). PLoS One 2010; 5: e9872.
37. Cozzolino M, Pesaresi MG, Gerbino V, Grosskreutz J, Carrì MT. Amyotrophic lateral sclerosis: new insights into underlying molecular mechanisms and opportunities for therapeutic intervention. Antioxid Redox Signal 2012; 17: 1277-330.
38. Crawford DR, Wang Y, Schools GP, Kochheiser J, Davies KJ. Downregulation of mammalian mitochondrial RNAs during oxidative stress. Free Radic Biol Med 1997; 22: 551-9.
39. Dadon-Nachum M, Melamed E, Offen D. The "dying-back" phenomenon of motor neurons in ALS. J Mol Neurosci 2011; 43: 470-7.
40. de Graaf N, van Helden MJ, Textoris-Taube K, Chiba T, Topham DJ, Kloetzel PM, et al. PA28 and the proteasome immunosubunits play a central and independent role in the production of MHC class I-binding peptides in vivo. Eur J Immunol 2011; 41: 926-35.
41. Denarier E, Fourest-Lieuvin A, Bosc C, Pirollet F, Chapel A, Margolis RL, et al. Nonneuronal isoforms of STOP protein are responsible for microtubule cold stability in mammalian fibroblasts. Proc Natl Acad Sci USA 1998; 95: 6055-60.
42. De Vos KJ, Chapman AL, Tennant ME, Manser C, Tudor EL, Lau KF, et al. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum Mol Genet 2007; 16: 2720-8.
43. De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008; 31: 151-73.
44. Duffy LM, Chapman AL, Shaw PJ, Grierson AJ. The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 2011; 37: 336-52.
45. Dulloo AG, Samec S. Uncoupling proteins: their roles in adaptive thermogenesis and substrate metabolism reconsidered. Br J Nutr 2001; 86: 123-39.
46. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30: 207-10.
47. Ende N, Weinstein F, Chen R, Ende M. Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). Life Sci 2000; 67: 53-9.
48. Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 2012; 322: 254-62.
49. Ferraiuolo L, Heath PR, Holden H, Kasher P, Kirby J, Shaw PJ. Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J Neurosci 2007; 27: 9201-19.
50. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol 2011; 7: 616-30.
51. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 2004; 185: 232-40.
52. Freria CM, Zanon RG, Santos LM, Oliveira AL. Major histocompatibility complex class I expression and glial reaction influence spinal motoneuron synaptic plasticity during the course of experimental autoimmune encephalomyelitis. J Comp Neurol 2010; 518: 990-1007.
53. Fulkerson PC, Zimmermann N, Hassman LM, Finkelman FD, Rothenberg ME. Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFN-gamma. J Immunol 2004; 173: 7565-74.
54. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
55. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010; 140: 918-34.
56. Gurney ME. Transgenic-mouse model of amyotrophic lateral sclerosis. N Engl J Med 1994; 331: 1721-2.
57. Heeger PS, Kemper C. Novel roles of complement in T effector cell regulation. Immunobiology 2012; 217: 216-24.
58. Heiman-Patterson TD, Deitch JS, Blankenhorn EP, Erwin KL, Perreault MJ, Alexander BK, et al. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J Neurol Sci 2005; 236: 1-7.
59. Heiman-Patterson TD, Sher RB, Blankenhorn EA, Alexander G, Deitch JS, Kunst CB, et al. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers. Amyotroph Lateral Scler 2011; 12: 79-86.
60. Henkel JS, Engelhardt JI, Sikló s L, Simpson EP, Kim SH, Pan T, et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 2004; 55: 221-35.
61. Henkel JS, Beers DR, Sikló s L, Appel SH. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol Cell Neurosci 2006; 31: 427-37.
62. Heurich B, El Idrissi NB, Donev RM, Petri S, Claus P, Neal J, et al. Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. J Neuroimmunol 2011; 235: 104-9.
63. Hu GF, Kishikawa H. Angiogenin and amyotrophic lateral sclerosis. United States Patent Application Publication. 2011. US 2011/0078804 A.
64. Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 2001; 193: 713-26.
65. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
66. Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ. Functional requirement for class I MHC in CNS development and plasticity. Science 2000; 290: 2155-9.
67. Ishii T, Mombaerts P. Expression of nonclassical class I major histocompatibility genes defines a tripartite organization of the mouse vomeronasal system. J Neurosci 2008; 28: 2332-41.
68. Jaarsma D, Teuling E, Haasdijk ED, De Zeeuw CI, Hoogenraad CC. Neuronspecific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J Neurosci 2008; 28: 2075-88.
69. Jahn R, Scheller RH. SNAREs-engines for membrane fusion. Nat Rev Mol Cell Biol 2006; 7: 631-43.
70. Jena BP. Role of SNAREs in membrane fusion. Adv Exp Med Biol 2011; 713: 13-32.
71. Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther 2012; 342: 619-30.
72. Jung KA, Kwak MK. The Nrf2 system as a potential target for the development of indirect antioxidants. Molecules 2010; 15: 7266-91.
73. Jung C, Higgins CM, Xu Z. A quantitative histochemical assay for activities of mitochondrial electron transport chain complexes in mouse spinal cord sections. J Neurosci Methods 2002a; 114: 165-72.
74. Jung C, Higgins CM, Xu Z. Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. J Neurochem 2002b; 83: 535-45.
75. Kanai Y, Okada Y, Tanaka Y, Harada A, Terada S, Hirokawa N. KIF5C, a novel neuronal kinesin enriched in motor neurons. J Neurosci 2000; 20: 6374-84.
76. Kapeta S, Chondrogianni N, Gonos EASE. Nuclear erythroid factor 2-mediated proteasome activation delays senescence in human fibroblasts. J Biol Chem 2010; 285: 8171-84.
77. Karras GI, Jentsch S. The RAD6 DNA damage tolerance pathway operates uncoupled from the replication fork and is functional beyond S phase. Cell 2010; 141: 255-67.
78. Kato S. Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences. Acta Neuropathol 2008; 115: 97-114.
79. Kieran D, Sebastia J, Greenway MJ, King MA, Connaughton D, Concannon CG, et al. Control of motoneuron survival by angiogenin. J Neurosci 2008; 28: 14056-61.
80. Kirby J, Halligan E, Baptista MJ, Allen S, Heath PR, Holden H, et al. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain 2005; 128: 1686-706.
81. Kishikawa H, Wu D, Hu GF. Targeting angiogenin in therapy of amyotrophic lateral sclerosis. Expert Opin Ther Targets 2008; 12: 1229-42.
82. Kok SH, Hong CY, Kuo MY, Wang CC, Hou KL, Lin YT, et al. Oncostatin M-induced CCL2 transcription in osteoblastic cells is mediated by multiple levels of STAT-1 and STAT-3 signaling: an implication for the pathogenesis of arthritis. Arthritis Rheum 2009; 60: 1451-62.
83. Korolchuk VI, Schutz MM, Gó mez-Llorente C, Rocha J, Lansu NR, Collins SM, et al. Drosophila Vps35 function is necessary for normal endocytic trafficking and actin cytoskeleton organisation. J Cell Sci 2007; 120: 4367-76.
84. Kott E, Kott E, Livni E, Zamir R, Kuritzky A. Cell-mediated immunity to polio and HLA antigens in amyotrophic lateral sclerosis. Neurology 1979; 29: 1040-4.
85. Kraft AD, Johnson DA, Johnson JA. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 2004; 24: 1101-12.
86. Kraft AD, Lee JM, Johnson DA, Kan YW, Johnson JA. Neuronal sensitivity to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response element. J Neurochem 2006; 98: 1852-65.
87. Kraft AD, Resch JM, Johnson DA, Johnson JA. Activation of the Nrf2-ARE pathway in muscle and spinal cord during ALS-like pathology in mice expressing mutant SOD1. Exp Neurol 2007; 207: 107-17.
88. Kristal BS, Koopmans SJ, Jackson CT, Ikeno Y, Park BJ, Yu BP. Oxidantmediated repression of mitochondrial transcription in diabetic rats. Free Radic Biol Med 1997; 22: 813-22.
89. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, Ransohoff RM, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006; 129: 200-11.
90. Lee JM, Shih AY, Murphy TH, Johnson JA. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 2003; 278: 37948-56.
91. Lee MJ, Lee BH, Hanna J, King RW, Finley D. Trimming of ubiquitin chains by proteasome-Associated deubiquitinating enzymes. Mol Cell Proteomics 2011; 10R110.003871.
92. Li S, Hu GF. Angiogenin-mediated rRNA transcription in cancer and neurodegeneration. Int J Biochem Mol Biol 2010; 1: 26-35.
93. Linda H, Hammarberg H, Cullheim S, Levinovitz A, Khademi M, Olsson T. Expression of MHC class I and beta2-microglobulin in rat spinal motoneurons: regulatory influences by IFN-gamma and axotomy. Exp Neurol 1998; 150: 282-95.
94. Liu X, Milo M, Lawrence ND, Rattray M. Probe-level measurement error improves accuracy in detecting differential gene expression. Bioinformatics 2006; 22: 2107-13.
95. Lo KW, Kogoy JM, Pfister KK. The DYNLT3 light chain directly links cytoplasmic dynein to a spindle checkpoint protein, Bub3. J Biol Chem 2007; 282: 11205-12.
96. Lobsiger CS, Boillé e S, Cleveland DW. Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc Natl Acad Sci USA 2007; 104: 7319-26.
97. Lobsiger CS, Cleveland DW. Glial cells as intrinsic components of noncellautonomous neurodegenerative disease. Nat Neurosci 2007; 10: 1355-60.
98. Longatti A, Tooze SA. Vesicular trafficking and autophagosome formation. Cell Death Differ 2009; 16: 956-65.
99. Magrané J, Manfredi G. Mitochondrial function, morphology, and axonal transport in amyotrophic lateral sclerosis. Antioxid Redox Signal 2009; 11: 1615-26.
100. Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 2008; 28: 6333-41.
101. Mancuso R, Olivá n S, Mancera P, Pasté n-Zamorano A, Manzano R, Casas C, et al. Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012; 13: 302-10.
102. Maragakis NJ, Rothstein JD. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2006; 2: 679-89.
103. Martinez-Arca S, Coco S, Mainguy G, Schenk U, Alberts P, Bouillé P, et al. A common exocytotic mechanism mediates axonal and dendritic outgrowth. J Neurosci 2001; 21: 3830-8.
104. Mead RJ, Higginbottom A, Bennett E, Kirby J, Barber SC, Allen SP, et al. Pharmacological NRF2-ARE pathway activation is protective in mouse and patient fibroblast models of amyotrophic lateral sclerosis. Free Radic Biol Med 2013; 61C: 438-452.
105. Medana I, Martinic MA, Wekerle H, Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001; 159: 809-15.
106. Miller KE, Sheetz MP. Axonal mitochondrial transport and potential are correlated. J Cell Sci 2004; 117: 2791-804.
107. Millecamps S, Julien JP. Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci 2013; 14: 161-76.
108. Mills EM, Xu D, Fergusson MM, Combs CA, Xu Y, Finkel T. Regulation of cellular oncosis by uncoupling protein 2. J Biol Chem 2002; 277: 27385-92.
109. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009; 15: 781-7.
110. Mukherjee P, Pasinetti GM. Complement anaphylatoxin C5a neuroprotects through mitogen-Activated protein kinase-dependent inhibition of caspase 3. J Neurochem 2001; 77: 43-9.
111. Mukherjee P, Thomas S, Pasinetti GM. Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. J Neuroinflammation 2008; 5: 5.
112. Nagata T, Nagano I, Shiote M, Narai H, Murakami T, Hayashi T, et al. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol Res 2007; 29: 772-6.
113. Nakayama A, Odajima T, Murakami H, Mori N, Takahashi M. Characterization of two promoters that regulate alternative transcripts in the microtubule-Associated protein (MAP) 1A gene. Biochim Biophys Acta 2001; 1518: 260-6.
114. Nardo G, Pozzi S, Mantovani S, Garbelli S, Marinou K, Basso M, et al. Nitroproteomics of peripheral blood mononuclear cells from patients and a rat model of ALS. Antioxid Redox Signal 2009; 11: 1559-67.
115. Nardo G, Pozzi S, Pignataro M, Lauranzano E, Spano G, Garbelli S, et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One 2011; 6: e25545.
116. Nickerson DP, West M, Odorizzi G. Did2 coordinates Vps4-mediated dissociation of ESCRT-III from endosomes. J Cell Biol 2006; 175: 715-20.
117. O'Barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T, et al. Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 2001; 166: 4154-62.
118. Oliveira AL, Thams S, Lidman O, Piehl F, Hökfelt T, Kärre K, et al. A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. Proc Natl Acad Sci USA 2004; 101: 17843-8.
119. Osaka H, Mukherjee P, Aisen PS, Pasinetti GM. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem 1999; 73: 303-11.
120. Palmer KJ, Hughes H, Stephens DJ. Specificity of cytoplasmic dynein subunits in discrete membrane-Trafficking steps. Mol Biol Cell 2009; 20: 2885-99.
121. Papadimitriou D, Le Verche V, Jacquier A, Ikiz B, Przedborski S, Re DB. Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis 2010; 37: 493-502.
122. Parkinson N, Ince PG, Smith MO, Highley R, Skibinski G, Andersen PM, et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). MRC Proteomics in ALS Study; FReJA Consortium. Neurology 2006; 67: 1074-7.
123. Pearson RD, Liu X, Sanguinetti G, Milo M, Lawrence ND, Rattray M. puma: a Bioconductor package for propagating uncertainty in microarray analysis. BMC Bioinformatics 2009; 10: 211.
124. Perrin FE, Boisset G, Docquier M, Schaad O, Descombes P, Kato AC. No widespread induction of cell death genes occurs in pure motoneurons in an amyotrophic lateral sclerosis mouse model. Hum Mol Genet 2005; 14: 3309-20.
125. Perrin FE, Boisset G, Lathuiliè re A, Kato AC. Cell death pathways differ in several mouse models with motoneurone disease: analysis of pure motoneurone populations at a presymptomatic age. Neurochem 2006; 98: 1959-72.
126. Peviani M, Caron I, Pizzasegola C, Gensano F, Tortarolo M, Bendotti C. Unraveling the complexity of amyotrophic lateral sclerosis: recent advances from the transgenic mutant SOD1 mice. CNS Neurol Disord Drug Targets 2010; 9: 491-503.
127. Pickering AM, Koop AL, Teoh CY, Ermak G, Grune T, Davies KJ. The immunoproteasome, the 20S proteasome and the PA28-b proteasome regulator are oxidative-stress-Adaptive proteolytic complexes. Biochem J 2010; 432: 585-94.
128. Pickering AM, Linder RA, Zhang H, Forman HJ, Davies KJ. Nrf2-dependent induction of proteasome and Pa28-b regulator are required for adaptation to oxidative stress. J Biol Chem 2012; 287: 10021-31.
129. Pizzasegola C, Caron I, Daleno C, Ronchi A, Minoia C, Carrì MT, et al. Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph Lateral Scler 2009; 10: 221-8.
130. Qiu XB, Ouyang SY, Li CJ, Miao S, Wang L, Goldberg AL. hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37. EMBO J 2006; 25: 5742-53.
131. Rattray M, Liu X, Sanguinetti G, Milo M, Lawrence ND. Propagating uncertainty in microarray data analysis. Brief Bioinform 2006; 7: 37-47.
132. Regnard C, Fesquet D, Janke C, Boucher D, Desbruyé res E, Koulakoff A, et al. Characterisation of PGs1, a subunit of a protein complex co-purifying with tubulin polyglutamylase. J Cell Sci 2003; 116: 4181-90.
133. Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 2013; 14: 248-64.
134. Rus H, Cudrici C, Niculescu F. The role of the complement system in innate immunity. Immunol Res 2005; 33: 103-12.
135. Sann S, Wang Z, Brown H, Jin Y. Roles of endosomal trafficking in neurite outgrowth and guidance. Trends Cell Biol 2009; 19: 317-24.
136. Santos MS, Li H, Voglmaier SM. Synaptic vesicle protein trafficking at the glutamate synapse. Neuroscience 2009; 158: 189-203.
137. Sarafi MN, Garcia-Zepeda EA, MacLean JA, Charo IF, Luster AD. Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural and functional homologue of human MCP-1. J Exp Med 1997; 185: 99-109.
138. Sarlette A, Krampfl K, Grothe C, Neuhoff N, Dengler R, Petri S. Nuclear erythroid 2-related factor 2 antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2008; 67: 1055-1062.
139. Saro D, Li T, Rupasinghe C, Paredes A, Caspers N, Spaller MR. A thermodynamic ligand binding study of the third PDZ domain (PDZ3) from the mammalian neuronal protein PSD-95. Biochemistry 2007; 46: 6340-52.
140. Saxena S, Cabuy E, Caroni P. A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat Neurosci 2009; 12: 627-36.
141. Schmitt-John T, Drepper C, Mussmann A, Hahn P, Kuhlmann M, Thiel C, et al. Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the wobbler mouse. Nat Genet 2005; 37: 1213-5.
142. Sebastià J, Kieran D, Breen B, King MA, Netteland DF, Joyce D, et al. Angiogenin protects motoneurons against hypoxic injury. Cell Death Differ 2009; 16: 1238-47.
143. Senaldi G, Varnum BC, Sarmiento U, Starnes C, Lile J, Scully S, et al. Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. Proc Natl Acad Sci USA 1999; 96: 11458-63.
144. Serviddio G, Bellanti F, Tamborra R, Rollo T, Capitanio N, Romano AD, et al. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-Alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut 2008; 57: 957-65.
145. Shatz CJ. MHC class I: an unexpected role in neuronal plasticity. Neuron 2009; 64: 40-5.
146. Shi P, Gal J, Kwinter DM, Liu X, Zhu H. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim Biophys Acta 2010; 1802: 45-51.
147. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 2003; 23: 3394-406.
148. Shinjyo N, Sta hlberg A, Dragunow M, Pekny M, Pekna M. Complementderived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem Cells 2009; 27: 2824-32.
149. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005; 37: 806-8.
150. Skorupa A, King MA, Aparicio IM, Dussmann H, Coughlan K, Breen B, et al. Motoneurons secrete angiogenin to induce RNA cleavage in astroglia. J Neurosci 2012; 32: 5024-38.
151. Storey JD. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann Statist 2006; 31: 2013-35.
152. Tanaka M, Kikuchi H, Ishizu T, Minohara M, Osoegawa M, Motomura K, et al. Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006; 65: 816-25.
153. Tararuk T, Ostman N, Li W, Björkblom B, Padzik A, Zdrojewska J, et al. JNK1 phosphorylation of SCG10 determines microtubule dynamics and axodendritic length. J Cell Biol 2006; 173: 265-77.
154. Taylor AM, Berchtold NC, Perreau VM, Tu CH, Li Jeon N, Cotman CW. Axonal mRNA in uninjured and regenerating cortical mammalian axons. J Neurosci 2009; 29: 4697-707.
155. Teuling E, Ahmed S, Haasdijk E, Demmers J, Steinmetz MO, Akhmanova A, et al. Motor neuron disease-Associated mutant vesicle-Associated membrane protein-Associated protein (VAP) B recruits wild-Type VAPs into endoplasmic reticulum-derived tubular aggregates. J Neurosci 2007; 27: 9801-15.
156. Thams S, Brodin P, Plantman S, Saxelin R, Kärre K, Cullheim S. Classical major histocompatibility complex class I molecules in motoneurons: new actors at the neuromuscular junction. J Neurosci 2009; 29: 13503-15.
157. Thomas A, Gasque P, Vaudry D, Gonzalez B, Fontaine M. Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol 2000; 12: 1015-23.
158. Tiwari JL, Terasaki PI. HLA and disease associations. New York: Springer-Verlag; 1985.
159. Tocco G, Musleh W, Sakhi S, Schreiber SS, Baudry M, Pasinetti GM. Complement and glutamate neurotoxicity. Genotypic influences of C5 in a mouse model of hippocampal neurodegeneration. Mol Chem Neuropathol 1997; 31: 289-300.
160. Tong L, Smyth D, Kerr C, Catterall J, Richards CD. Mitogen-Activated protein kinases Erk1/2 and p38 are required for maximal regulation of TIMP-1 by oncostatin M in murine fibroblasts. Cell Signal 2004; 16: 1123-32.
161. Tsujino H, Kondo E, Fukuoka T, Dai Y, Tokunaga A, Miki K, et al. Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: a novel neuronal marker of nerve injury. Mol Cell Neurosci 2000; 15: 170-82.
162. Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 2008; 85: 94-134.
163. Van Beek J, Nicole O, Ali C, Ischenko A, MacKenzie ET, Buisson A, et al. Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport 2001; 12: 289-93.
164. Van Hoecke A, Schoonaert L, Lemmens R, Timmers M, Staats KA, Laird AS, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 2012; 18: 1418-22.
165. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 2008; 28: 13574-81.
166. Vlug AS, Teuling E, Haasdijk ED, French P, Hoogenraad CC, Jaarsma D. ATF3 expression precedes death of spinal motoneurons in amyotrophic lateral sclerosis-SOD1 transgenic mice and correlates with c-Jun phosphorylation, CHOP expression, somato-dendritic ubiquitination and Golgi fragmentation. Eur J Neurosci 2005; 22: 1881-94.
167. Wahl AF, Wallace PM. Oncostatin M in the anti-inflammatory response. Ann Rheum Dis 2001; 60 (Suppl 3): iii75-80.
168. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J 1992; 281: 21-40.
169. Wallace PM, MacMaster JF, Rouleau KA, Brown TJ, Loy JK, Donaldson KL, et al. Regulation of inflammatory responses by oncostatin M. J Immunol 1999; 162: 5547-55
170. Erratum in: J Immunol 2000; 164: 5531.
171. Weiss TW, Kvakan H, Kaun C, Zorn G, Speidl WS, Pfaffenberger S, et al. The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through ERK1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: a possible role for the gp130/gp130 ligand system in the modulation of extracellular matrix degradation in the human heart. J Mol Cell Cardiol 2005; 39: 545-551.
172. Weiss TW, Samson AL, Niego B, Daniel PB, Medcalf RL. Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo. FASEB J 2006; 20: 2369-71.
173. Xia CH, Roberts EA, Her LS, Liu X, Williams DS, Cleveland DW, Goldstein LS. Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. J Cell Biol 2003; 161: 55-66.
174. Yamanak K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008; 11: 251-3.
175. Yanamadala V, Friedlander RM. Complement in neuroprotection and neurodegeneration. Trends Mol Med 2010; 16: 69-76.
176. Yao T, Song L, Xu W, DeMartino GN, Florens L, Swanson SK, et al. Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat Cell Biol 2006; 8: 994-1002.
177. Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000; 96: 569-76.
178. Yi FH, Lautrette C, Vermot-Desroches C, Bordessoule D, Couratier P, Wijdenes J, et al. In vitro induction of neuronal apoptosis by anti-Fas antibody-containing sera from amyotrophic lateral sclerosis patients. J Neuroimmunol 2000; 109: 211-20.
179. Yu JX, Bradt BM, Cooper NR. Constitutive expression of proinflammatory complement components by subsets of neurons in the central nervous system. J Neuroimmunol 2002; 123: 91-101.
180. Zacchigna S, Lambrechts D, Carmeliet P. Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 2008; 9: 169-81.
181. Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2001; 2: 107-17.
182. Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, O'Banion MK, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 2008; 11: 420-2.